Male breast cancer: a neglected disease

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2019-12-01 DOI:10.2217/bmt-2019-0020

I. Fentiman

引用次数: 4

Abstract

Male breast cancer (MBC) is rare, tending to afflict sedentary men, with adolescent obesity being a risk factor. Men fare worse compared with matched females with breast cancer. The preponderance of ER+ve disease affects the molecular profile: most cases have luminal A tumors. Through male ignorance and risk-taking, delay is frequent and this lacuna needs addressing with health education. The major gene mutation responsible for MBC is BRCA2. Five single nucleotide polymorphisms (SNPs) are significantly and uniquely associated with MBC risk with two located in the 8q24.21 regions. Mastectomy is being gradually replaced by nipple-preserving surgery and radiotherapy but this trend could be expedited with neoadjuvant endocrine therapy. Significant advances will occur only after expansion of collaborative groups and this is a matter of pressing importance.

查看原文本刊更多论文

男性乳腺癌:一种被忽视的疾病

男性癌症（MBC）是罕见的，常折磨久坐不动的男性，青少年肥胖是一个危险因素。与患有癌症的女性相比，男性的情况更糟。ER+ve疾病的优势影响分子特征：大多数病例都有管腔A肿瘤。由于男性的无知和冒险行为，拖延是经常发生的，这一缺陷需要通过健康教育来解决。引起MBC的主要基因突变是BRCA2。五个单核苷酸多态性（SNPs）与MBC风险显著且独特相关，其中两个位于8q24.21区域。乳房切除术正逐渐被保留乳头的手术和放疗所取代，但新辅助内分泌治疗可能会加快这一趋势。只有在扩大协作小组之后，才能取得重大进展，这是一个紧迫的重要问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.